Lorcaserin
Product Name:
Product Name: Lorcaserin
Synonyms: (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;Apd 356;Apd356;Apd-
356;Ar-10a;Unii-637E494o0z;(1R)-8-Chloro-2,3,4,5-tetrahydro-1-Methyl-1H-3-benzazepine
CAS: 616202-92-7
MF: C11H14ClN
MW: 195.692
EINECS: 1308068-626-2
Product Categories: Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine
Boiling point 288°C
density 1.075
Fp 128 o°C
storage temp. -20°C Freezer
Appearance: White Powder
COA:
| ITEMS | SPECIFICATION | TESTRESULTS |
| Appearance | Off-white or white powder | Conforms |
| Identification | HPLC,NMR;LC-MS | Conforms |
| Related substances | Individual impurity≤0.5% | 0.09% |
| Total impurities≤1.0% | 0.20% |
| Loss on drying | ≤0.5% | 0.3% |
| Residue on ignition | ≤0.1% | 0.04% |
| Heavy metals | ≤10ppm | Conforms |
| Assay | ≥98.0 % | 99.1% |
Weight loss drugs:
Lorcaserin is a new drug for the treatment of obesity , belonging to oral potent selective
serotonin 2C receptor agonists, lorcaserin hydrochloride is successfully developed by the
US company Arena, on June 27, 2012 by the US FDA it is approved for marketing, as adjuvant
therapy for obesity or merge with at least one weight-related complications in overweight
adults in low-calorie diet and exercise basis . Clinical studies show that the drug can
reduce weight of obesity and overweight patients ,it can improve obesity-related metabolic
parameters, and it is well tolerated. Lorcaserin affinity for the 5-HT2c 100 times higher
than the 5-HT2B (valvular heart disease risk) ,it has good safety,it is the first FDA-
approved weight-loss drug after 1999 . In a year of Lorcaserin treatment, the average
weight loss ranges from 3 to 3.7 percent.
Drug Interactions:
Due to the theoretical possibility of the mechanism of lorcaserin and serotonin syndrome,
when lorcaserin is used in combination with the serotonergic neurotransmitter system drugs,
extreme caution should be paid, including triptans monoamine oxidase inhibitor agent
selective serotonin reuptake inhibitor selective serotonin and norepinephrine reuptake
inhibitors, tricyclic antidepressants bupropion dextromethorphan, lithium tramadol and St.
John's wort , etc. In addition, when the present product with CYP2D6 substrates when
combined with the need to be cautious, because the product can increase the exposure of
these drugs.
Safety:
Lorcaserin has good tolerability and safety, lorcaserin is used in non-diabetic patients,
the most common adverse reactions are headache, dizziness, fatigue, nausea, dry mouth and
constipation. This product is used in patients with diabetes, common adverse reactions are
headache, back pain, cough, low blood sugar and fatigue.studies have found that lorcaserin
and placebo are Similar in the proportion of serious adverse reactions, lorcaserin does not
increase the incidence of valvular heart disease. After lorcaserin treatment , the
incidence of depression is lower , the research shows that the proportion of depression led
by lorcaserin 10mgbid, 10mgqd and placebo are 1.9%, 1.1% and 1.8%, emotional low incidence
rates are 0.6%, 0.9% and 0.9%, the proportion of suicidal thoughts are 0.9%, 0.6% and 0.7%
.the product is pregnancy X-class , pregnant women are disabled; whether this product is
secreted by milk is unknown, breast-feeding women need to weigh on the use of the drug;
this product is not recommended for children.
Uses:
1. diet pills
2. A novel selective 5-HT2C-receptor agonist for the treatment of obesity.
Definition ChEBI:
A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a
methyl group and a t position 6 by a chloro group.
